SunTrust Banks Inc. set a $48.00 price objective on Fresenius Medical Care AG (NYSE:FMS) in a research note released on Thursday morning. The brokerage currently has a a buy rating on the stock.

Several other equities analysts also recently commented on FMS. DZ Bank AG reissued a neutral rating on shares of Fresenius Medical Care AG in a report on Thursday, August 4th. Goldman Sachs Group Inc. reissued a buy rating on shares of Fresenius Medical Care AG in a report on Tuesday, September 13th. Berenberg Bank reissued a buy rating on shares of Fresenius Medical Care AG in a report on Tuesday, August 9th. Citigroup Inc. raised shares of Fresenius Medical Care AG from a neutral rating to a buy rating in a report on Tuesday, September 6th. Finally, Jefferies Group raised shares of Fresenius Medical Care AG from an underperform rating to a hold rating in a report on Friday, July 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Fresenius Medical Care AG has a consensus rating of Hold and an average target price of $44.33.

Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 0.12% during midday trading on Thursday, reaching $41.70. 50,669 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $43.77 and its 200-day moving average is $43.81. The stock has a market cap of $25.50 billion, a PE ratio of 23.12 and a beta of 0.58. Fresenius Medical Care AG has a 12-month low of $38.71 and a 12-month high of $47.52.

Fresenius Medical Care AG (NYSE:FMS) last released its earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.92 by $0.04. Fresenius Medical Care AG had a net margin of 6.40% and a return on equity of 9.66%. The firm had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.54 billion. On average, equities analysts expect that Fresenius Medical Care AG will post $2.01 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harding Loevner LP boosted its position in Fresenius Medical Care AG by 40.8% in the third quarter. Harding Loevner LP now owns 3,332,640 shares of the company’s stock worth $145,870,000 after buying an additional 966,390 shares during the last quarter. Cambiar Investors LLC boosted its position in shares of Fresenius Medical Care AG by 5.2% in the second quarter. Cambiar Investors LLC now owns 2,333,733 shares of the company’s stock valued at $101,681,000 after buying an additional 114,840 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Fresenius Medical Care AG by 23.2% in the first quarter. Royal Bank of Canada now owns 529,505 shares of the company’s stock valued at $23,340,000 after buying an additional 99,742 shares during the last quarter. Jarislowsky Fraser Ltd boosted its position in shares of Fresenius Medical Care AG by 2.9% in the second quarter. Jarislowsky Fraser Ltd now owns 316,131 shares of the company’s stock valued at $13,773,000 after buying an additional 9,015 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Fresenius Medical Care AG by 0.9% in the second quarter. Parametric Portfolio Associates LLC now owns 227,077 shares of the company’s stock valued at $9,894,000 after buying an additional 1,941 shares during the last quarter. Hedge funds and other institutional investors own 2.33% of the company’s stock.

Fresenius Medical Care AG Company Profile

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Stock Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related stocks with our FREE daily email newsletter.